$3.07
-0.08(-2.54%)
Mkt Cap $470M
$2.27
$5.00
52-Week Range
At a Glance
AI-generated8-K
Absci Corporation reported fourth quarter and full year 2025 financial results with Q4 revenue of $0.7 million and net loss of $29.6 million, and full year revenue of $2.8 million and net loss of $115.2 million. The company dosed first three cohorts in the ABS-201 Phase 1/2a HEADLINE trial, unveiled supporting ex vivo data, appointed Ransi Somaratne as Chief Medical Officer, and stated cash sufficient into first half of 2028.$470M
Market Cap
$3M
Revenue
-$120M
Net Income
Employees156
Fundamentals
How The Business Makes Money
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001672688
ISINUS00091E1091
CUSIP00091E109
Phone360 949 1041
Address18105 SE Mill Plain Boulevard, Vancouver, WA, 98683, US
SEC EDGAR